{"url":"https://lda.senate.gov/api/v1/filings/7fa49fdc-e884-4cfd-81b0-ea20b965c040/","filing_uuid":"7fa49fdc-e884-4cfd-81b0-ea20b965c040","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/7fa49fdc-e884-4cfd-81b0-ea20b965c040/print/","filing_document_content_type":"text/html","income":"45000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Kelly Childress","dt_posted":"2025-04-17T13:55:50-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1000 Wisconsin Ave., NW","registrant_address_2":"Suite 200","registrant_different_address":true,"registrant_city":"Wasington","registrant_state":"DC","registrant_zip":"20007","registrant":{"id":400646949,"url":"https://lda.senate.gov/api/v1/registrants/400646949/","house_registrant_id":null,"name":"EAST END GROUP, LLC","description":"Consulting and government affairs.","address_1":"3 W. Irving St.","address_2":"Suite 200","address_3":null,"address_4":null,"city":"Chevy Chase","state":"MD","state_display":"Maryland","zip":"20815","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"KELLY CHILDRESS LANGE","contact_telephone":"+1 202-688-1814","dt_updated":"2026-07-29T12:19:27.077010-04:00"},"client":{"id":193834,"url":"https://lda.senate.gov/api/v1/clients/193834/","client_id":315,"name":"ALVOGEN","general_description":"Pharmaceutical company developing and manufacturing generic, brand and biosimilar products","client_government_entity":false,"client_self_select":null,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2018-08-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals.","foreign_entity_issues":"Alvogen Luxembourg SARL; Temasek Singapore","lobbyists":[{"lobbyist":{"id":60906,"prefix":null,"prefix_display":null,"first_name":"ANDREW","nickname":null,"middle_name":null,"last_name":"HAWKINS","suffix":null,"suffix_display":null},"covered_position":"Rep. Rogers, LA, Chief of Staff.","new":false},{"lobbyist":{"id":150526,"prefix":"mrs","prefix_display":"MRS.","first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"CHILDRESS LANGE","suffix":null,"suffix_display":null},"covered_position":"Rep. Shimkus, LA; Rep. Rogers, Health Policy Adviser.","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}